Using coenzyme Q10 supplements to manage or prevent statin-induced muscle symptoms

18 February 2022People often buy coenzyme Q10 supplements to help with statin-induced muscle symptoms. However, there is insufficient evidence to recommend its use.

Using miconazole oral gel to treat oral thrush in adults taking a statin

30 November 2021Treatment of oral thrush (candidiasis) with miconazole is complicated by concurrent HMG-CoA reductase (statin) use because of potential for drug interactions.

Statin formulations suggested for adults with swallowing difficulties

1 July 2021A range of statins are suitable for adults with swallowing difficulties.

Is there an interaction between erythromycin and statins?

2 October 2020This updated Medicines Q&A evaluates the evidence for an interaction between erythromycin and statins. Summary: Erythromycin raises the plasma levels of statins which are metabolised…

Safety in Lactation: Drugs for hyperlipidaemias

25 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. There is no evidence for the…
Search Articles

Medicine Compliance Aid Stability

LipitorPfizer Ltd

Pfizer Ltd
Tablets f/c 10mg, 20mg, 40mg, 80mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Store in well-closed containers. Protect from light.
9 November 2015

Lactation Safety Information

Bile acid sequestrants (if appropriate)
No published evidence of safety
Possible impact on neonatal development
Serious adverse effects reported in adults
29 July 2020

New Medicines

Hypercholesterolaemia and prevention of cardiovascular disease - oral suspension formulation


New formulation
Not Known

Development and Regulatory status

March 2022
Mar 22Available in the UK. Price for 20mg/5ml oral suspension (sugar free), 1 x 150mL = £198.76 [3].
Jan 22MHRA approves atorvastatin 4mg/ml oral suspension for use as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Also to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. And also for prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors [2].


A selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Formulated as a 4mg/ml oral suspension. Store at room temperature, has a 60 day shelf-life once opened.
The UK population has one of the highest average serum cholesterol levels in the world. Two thirds of the UK population have a serum cholesterol level greater than 5.2 mmol/L [1].
Hypercholesterolaemia and prevention of cardiovascular disease - oral suspension formulation